AstraZeneca PLC (ETR:ZEG)
Germany
· Delayed Price · Currency is EUR | Market Cap | 187.74B |
| Revenue (ttm) | 52.23B |
| Net Income (ttm) | 6.80B |
| Shares Out | n/a |
| EPS (ttm) | 4.35 |
| PE Ratio | 27.63 |
| Forward PE | n/a |
| Dividend | 2.93 (2.47%) |
| Ex-Dividend Date | Feb 20, 2025 |
| Volume | 11,436 |
| Average Volume | 25,794 |
| Open | 120.65 |
| Previous Close | 121.05 |
| Day's Range | 120.35 - 122.40 |
| 52-Week Range | 111.00 - 158.20 |
| Beta | 0.25 |
| RSI | 40.64 |
| Earnings Date | Apr 29, 2025 |
About AstraZeneca
AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company offers Imjudo, Datroway, Iressa, Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Crestor, Seloken, Lokelma, Roxadustat, Andexxa, Wainua, Symbicort, Fasenra, Pulmicort, Breztri/Trixeo, Saphnelo, Tezspire, Airsupra, Ultomiris, Soliris, Strensiq, Koselugo, Kanuma, Atacand, Plendil, Modip, Splendil, Munobal, Flodil, Komboglyze, Qtern, B... [Read more]
Financial Performance
In 2024, AstraZeneca's revenue was $54.07 billion, an increase of 18.03% compared to the previous year's $45.81 billion. Earnings were $7.04 billion, an increase of 18.14%.
Financial numbers in USD Financial StatementsNews
Tempus AI Stock Is Ripping Higher Wednesday: What's Fueling The Move?
Tempus AI Inc (NASDAQ: TEM) shares are surging Wednesday after the company announced a multi-year collaboration with AstraZeneca PLC (NASDAQ: AZN) and Pathos AI . What To Know: Tempus AI announced a...
Drug firm bosses call for price increases in Europe amid tariff uncertainty
The boss of AstraZeneca said Europe should increase spending on health treatment in line with recent commitments on defence.
Tempus expands partnership with AstraZeneca to build oncology model
Tempus AI (NASDAQ:TEM) partners with AstraZeneca & Pathos AI on a multimodal oncology model. Read more here.
Tempus Signs Expanded Strategic Agreements with AstraZeneca and Pathos to Develop the Largest Multimodal Foundation Model in Oncology
Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, today announced multi-year, strategic collaborations with AstraZeneca (LS...
Tempus Signs Expanded Strategic Agreements with AstraZeneca and Pathos to Develop the Largest Multimodal Foundation Model in Oncology
CHICAGO--(BUSINESS WIRE)--Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, today announced multi-year, strategic collabora...
AstraZeneca CEO says Europe must protect its health sovereignty, is falling behind on pharma investments
AstraZeneca Chief Executive Officer Pascal Soriot said on Wednesday that Europe has stepped up its defence spending and now must protect its health sovereignty amid a shifting world order.
AstraZeneca rejoins leading U.S. drug lobby group after two-year absence
AstraZeneca has rejoined the main U.S. drug lobby group, roughly two years after leaving it, the Pharmaceutical Research and Manufacturers of America (PhRMA) said on Tuesday.
AstraZeneca's Enhertu, pertuzumab combo improves breast cancer treatment in trial
LLY, NVO and AMGN Forecast – Pharma Stocks to Open Mixed
The three pharma stocks in this analysis all look a bit mixed in the premarket, after seeing some momentum late last week. This is especially true with LLY, as you will see on the charts.
ENHERTU® Plus Pertuzumab Demonstrated Highly Statistically Significant and Clinically Meaningful Improvement in Progression-Free Survival Versus THP as First-Line Therapy for Patients with HER2 Positive Metastatic Breast Cancer
DESTINY-Breast09 phase 3 trial of Daiichi Sankyo and AstraZeneca's ENHERTU is the first trial in more than a decade to demonstrate superior efficacy across a broad HER2 positive metastatic patient pop...
Selling America, Buying Europe - My Picks
After years of strong returns, amidst the tariff-induced uncertainty, I am rotating towards European-based equities. US economy is facing mounting pressures, via weakening consumer demand, reduced CAP...
Bruce Murray's Past Picks: Alphabet, AstraZeneca & Manulife
Bruce Murray, CEO and CIO at Murray Wealth Group, discusses his past stock picks and how they're doing in the market today.
European pharma companies issue demands to stay in EU ahead of expected US tariffs
Nearly three dozen global pharmaceutical companies, in a letter to the head of the European Commission, demanded help to maintain operations in the EU despite threatened U.S. tariffs on imports, inclu...
Trump Says Pharmaceutical Tariffs Coming in Near Future
President Donald Trump said tariffs on pharmaceuticals will be coming in the “not too distant future” and fit in the category of tariffs imposed on cars, steel, and aluminum. Trump spoke with reporter...
Trump says US pharma tariffs coming in not-too-distant future
U.S. President Donald Trump said on Monday that he expects to impose tariffs on imported pharmaceuticals in the not-too-distant future.
Trump's pharmaceutical tariffs could raise costs for patients, worsen drug shortages
President Donald Trump's planned tariffs on pharmaceuticals imported into the U.S. could have wide-ranging consequences on the drug supply chain, manufacturers and American patients, some experts told...
Autos, pharma, luxury and more: The global sectors soaring after Trump's tariffs walkback
European stocks soared on Thursday after U.S. President Donald Trump's jarring about-turn on most tariffs. Tensions between Washington and Beijing remain high, however, with Trump ratcheting up duties...
BMO's Siegerman talks the impact of tariffs on pharmaceutical stocks
Evan Seigerman, BMO, joins 'Fast Money' to talk the impact of tariffs on pharma space.
Trump's Tariffs Circle Pharma Industry: Who It Affects And How It May Play Out
The Trump administration's proposed tariffs on pharmaceuticals have caused significant market turmoil today, with major Pharma stocks plummeting globally. Despite pledges to increase U.S. manufacturin...
Explainer: Prescription drugs become a target in Trump's trade war
U.S. President Donald Trump late on Tuesday reiterated he would impose tariffs on imports of pharmaceutical products that have long been spared from past trade disputes due to the potential for harm t...
Healthy Returns: Trump says major pharmaceutical tariffs coming ‘very shortly'
Trump doubled down on plans to soon impose "major" pharmaceutical tariffs, while early stage startups dominated digital health funding deals in first quarter.
Pharma Stocks Slide Further After Trump Reiterates Tariff Threats on Drugs
Drugmakers have said they're still unclear about whether Trump will impose tariffs on finished products or on active pharmaceutical ingredients.
Pharmaceutical stocks fall as Trump doubles down on tariffs threat
Pharmaceutical stocks fell after President Donald Trump doubled down on plans to impose tariffs on pharmaceuticals imported into the U.S. "very shortly." Shares of Eli Lilly, AbbVie, Bristol Myers Squ...
Global pharma shares plunge as Trump doubles down on tariff threat
Global drugmakers' stocks dropped across the board after U.S. President Donald Trump reiterated plans for a "major" tariff on pharmaceutical imports, threatening an interwoven global supply chain, and...
Trump teases targeted tariffs on overseas drug manufacturers
With the next set of White House–imposed tariffs just hours away from taking effect — including the attention-hogging 104% rate to be levied on products from China as they're imported into the U.S. — ...